Tumours modulate the systemic vascular response to anti‐angiogenic therapy
Sign Up to like & getrecommendations! Published in 2022 at "Journal of Applied Toxicology"
DOI: 10.1002/jat.4301
Abstract: Toxicologic evaluation of new drug candidates routinely utilizes healthy animals. In oncology, there remains a limited understanding of the effects of novel test candidates in a diseased host. For vascular modulating agents (VMAs), an increased… read more here.
Keywords: tumour host; growth; modulate systemic; anti angiogenic ... See more keywords
Tumour and host cell PD-L1 is required to mediate suppression of anti-tumour immunity in mice
Sign Up to like & getrecommendations! Published in 2017 at "Nature Communications"
DOI: 10.1038/ncomms14572
Abstract: Expression of PD-L1, the ligand for T-cell inhibitory receptor PD-1, is one key immunosuppressive mechanism by which cancer avoids eradication by the immune system. Therapeutic use of blocking antibodies to PD-L1 or its receptor PD-1… read more here.
Keywords: tumour host; suppression; required mediate; cell required ... See more keywords
Adverse Tumour and Host Biology May Explain the Poorer Outcomes Seen in Emergency Presentations of Colon Cancer.
Sign Up to like & getrecommendations! Published in 2023 at "Annals of surgery"
DOI: 10.1097/sla.0000000000005872
Abstract: OBJECTIVE To examine the association between tumour/host factors (including the systemic inflammatory response), mode of presentation and short/long-term outcomes in patients undergoing curative resectional surgery for TNM I-III colon cancer. SUMMARY BACKGROUND DATA Emergency presentations… read more here.
Keywords: emergency; tumour host; biology; colon cancer ... See more keywords